Insider · CIK 0001805097

Ballal Rahul D.

Reports to the SEC for 2 companies · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001805097

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-18	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsA Award	Director	AAward	+2,927 sh	—	—	2,927
2026-06-18	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+2,816 sh	—	—	15,230
2026-06-18	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Director	MExercise/Conversion	−2,816 sh	—	—	0
2026-06-18	AGIOAGIOS PHARMACEUTICALS, INC. · Stock options (right to buy)A Award	Director	AAward	+15K sh	—	—	14,950
2026-02-12	ELVNEnliven Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+17.1K sh	—	—	17,126
2025-08-11	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Director	MExercise/Conversion	−2,302 sh	—	—	0
2025-08-11	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+2,302 sh	—	—	12,414
2025-06-20	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Director	MExercise/Conversion	−2,120 sh	—	—	0
2025-06-20	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+2,120 sh	—	—	10,112
2025-06-18	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsA Award	Director	AAward	+2,816 sh	—	—	2,816
2025-06-18	AGIOAGIOS PHARMACEUTICALS, INC. · Stock options (right to buy)A Award	Director	AAward	+15.8K sh	—	—	15,768
2025-02-06	ELVNEnliven Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+20.5K sh	—	—	20,491
2024-11-08	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Director	SSale	−1,500 sh	$59.21	−$88.8K	7,992
2024-11-08	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+10K sh	$25.99	+$260K	17,992
2024-11-08	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Director	SSale	−3,571 sh	$57.24	−$204K	14,421
2024-11-08	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Director	SSale	−4,929 sh	$58.57	−$289K	9,492
2024-11-08	AGIOAGIOS PHARMACEUTICALS, INC. · Stock option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−10K sh	—	—	17,947
2024-11-07	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Director	SSale	−8,132 sh	$53.32	−$434K	9,860
2024-11-07	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+10K sh	$25.99	+$260K	17,992
2024-11-07	AGIOAGIOS PHARMACEUTICALS, INC. · Stock option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−10K sh	—	—	27,947
2024-11-07	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Director	SSale	−1,868 sh	$54.41	−$102K	7,992
2024-10-08	ELVNEnliven Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−6,314 sh	—	—	69,428
2024-10-08	ELVNEnliven Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+4,106 sh	$5.52	+$22.7K	32,761
2024-10-08	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−10.4K sh	$28.17	−$294K	22,341
2024-10-08	ELVNEnliven Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−4,106 sh	—	—	12,322
2024-10-08	ELVNEnliven Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+6,314 sh	$19.68	+$124K	28,655
2024-08-11	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+2,302 sh	—	—	7,992
2024-08-11	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Director	MExercise/Conversion	−2,302 sh	—	—	2,302
2024-06-20	AGIOAGIOS PHARMACEUTICALS, INC. · Stock options (right to buy)A Award	Director	AAward	+11.8K sh	—	—	11,774
2024-06-20	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsA Award	Director	AAward	+2,120 sh	—	—	2,120
2024-06-13	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Director	MExercise/Conversion	−3,388 sh	—	—	0
2024-06-13	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+3,388 sh	—	—	5,690
2024-04-11	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−30.3K sh	$23.14	−$701K	45,441
2024-04-11	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−20K sh	$25.00	−$501K	25,409
2024-04-11	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−3,068 sh	$25.21	−$77.3K	22,341
2024-04-11	ELVNEnliven Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−48.8K sh	—	—	0
2024-04-11	ELVNEnliven Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−4,580 sh	—	—	75,742
2024-04-11	ELVNEnliven Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+48.8K sh	$12.60	+$615K	71,161
2024-04-11	ELVNEnliven Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+4,580 sh	$19.68	+$90.1K	75,741
2024-04-10	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−13.6K sh	$21.01	−$286K	22,341
2024-04-10	ELVNEnliven Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−13.6K sh	—	—	48,820
2024-04-10	ELVNEnliven Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+13.6K sh	$12.60	+$171K	35,941
2024-04-04	ELVNEnliven Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,485 sh	$12.60	+$43.9K	25,826
2024-04-04	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−3,485 sh	$19.15	−$66.7K	22,341
2024-04-04	ELVNEnliven Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−3,485 sh	—	—	62,420
2024-04-01	ELVNEnliven Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+94 sh	$12.60	+$1,184.4	22,435
2024-04-01	ELVNEnliven Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,143 sh	$5.52	+$17.3K	25,578
2024-04-01	ELVNEnliven Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−94 sh	—	—	65,905
2024-04-01	ELVNEnliven Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−3,143 sh	—	—	16,428
2024-04-01	ELVNEnliven Therapeutics, Inc.S Sale	Director	SSale	−3,237 sh	$19.08	−$61.8K	22,341

Recent filings

Accepted (ET)
Jun 234
Ballal Rahul D.0001439222-26-000107
SEC(opens sec.gov)
Feb 174
Ballal Rahul D.0001805097-26-000001
SEC(opens sec.gov)
Aug 134
Ballal Rahul D.0001439222-25-000098
SEC(opens sec.gov)
Jun 234
Ballal Rahul D.0001439222-25-000061
SEC(opens sec.gov)
Feb 104
Ballal Rahul D.0001415889-25-003516
SEC(opens sec.gov)
Nov 124
Ballal Rahul D.0001439222-24-000142
SEC(opens sec.gov)

Companies

Address

C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET

CAMBRIDGE, MA, 02139